(Q34293601)

1 August 2017

1 reference

title

Potential roles of antisense technology in cancer chemotherapy (English)

1 reference

1 August 2017

1 reference

Crooke ST

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

1 August 2017

1 reference

1 August 2017

volume

19

1 reference

1 August 2017

issue

56

1 reference

1 August 2017

page(s)

6651-6659

1 reference

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Novel mechanisms for antisense-mediated regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Antisense oligonucleotides as a tool for gene functionalization and target validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Human Bcl-2 antisense therapy for lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Molecular mechanisms of action of antisense drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Site specific enzymatic cleavage of RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Purification and characterization of human ribonuclease HII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Alpha-DNA.IX: Parallel annealing of alpha-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Conformationally restricted carbohydrate-modified nucleic acids and antisense technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Biologic and therapeutic significance of MYB expression in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Antisense properties of peptide nucleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Implication of RNA structure on antisense oligonucleotide hybridization kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Morpholino antisense oligomers: the case for an RNase H-independent structural type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Molecular cloning and expression of cDNA for human RNase H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Properties of cloned and expressed human RNase H1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

Therapeutic Applications of Oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

Therapeutic applications of oligonucleotides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

Evaluating the mechanism of action of antiproliferative antisense drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204093

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204093

1 reference

Dimensions Publication ID

1 August 2017

1037897301

0 references

1 reference